发热性中性粒细胞减少症的管理与预防措施
Management and Preventive Measures for Febrile Neutropenia.
作者信息
Lucas Austin J, Olin Jacqueline L, Coleman Megan D
出版信息
P T. 2018 Apr;43(4):228-232.
Abstract
Febrile neutropenia (FN) is an oncological emergency and serious complication often resulting from chemotherapy. In patients with a weak or completely suppressed immune system, a fever may be the only sign of an underlying infection and immediate treatment is needed. Using risk evaluation scores, it is possible to stratify individual patient degree of risk. However, all patients warrant immediate antibiotic coverage. Antibiotic treatment of FN is broadened or narrowed based on individualized clinical scenarios. Prophylactic antimicrobials may be used in specific high-risk situations. This article briefly reviews FN, describes risk assessment tools, and discusses treatment and prophylactic options.
摘要
发热性中性粒细胞减少症（FN）是一种肿瘤急症和严重并发症，常由化疗引起。在免疫系统薄弱或完全受抑制的患者中，发热可能是潜在感染的唯一迹象，需要立即进行治疗。通过风险评估评分，可以对个体患者的风险程度进行分层。然而，所有患者都需要立即给予抗生素覆盖。FN的抗生素治疗会根据个体化临床情况进行调整，扩大或缩小用药范围。预防性抗菌药物可用于特定的高风险情况。本文简要回顾了FN，描述了风险评估工具，并讨论了治疗和预防方案。
相似文献
1
Management and Preventive Measures for Febrile Neutropenia.发热性中性粒细胞减少症的管理与预防措施
P T. 2018 Apr;43(4):228-232.
2
Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.用于预防乳腺癌患者化疗引起的发热性中性粒细胞减少症的一级预防性集落刺激因子。
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD007913. doi: 10.1002/14651858.CD007913.pub2.
3
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.2010 年版 EORTC 指南更新：粒细胞集落刺激因子在降低淋巴增殖性疾病和实体瘤成人患者化疗所致发热性中性粒细胞减少症发生率中的应用
Eur J Cancer. 2011 Jan;47(1):8-32. doi: 10.1016/j.ejca.2010.10.013. Epub 2010 Nov 20.
4
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association.成人化疗所致中性粒细胞减少症的当前管理：要点和新挑战：中国抗癌协会肿瘤支持治疗专业委员会、中国抗癌协会临床化疗专业委员会。
Cancer Biol Med. 2020 Nov 15;17(4):896-909. doi: 10.20892/j.issn.2095-3941.2020.0069. Epub 2020 Dec 15.
5
Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.预防性 pegfilgrastim 预防接受每两周（Q2W）化疗方案的患者发热性中性粒细胞减少症：疗效、有效性和安全性的系统评价。
BMC Cancer. 2021 May 27;21(1):621. doi: 10.1186/s12885-021-08258-w.
6
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.欧洲癌症研究与治疗组织（EORTC）关于使用粒细胞集落刺激因子降低淋巴瘤和实体瘤成年患者化疗引起的发热性中性粒细胞减少症发生率的指南。
Eur J Cancer. 2006 Oct;42(15):2433-53. doi: 10.1016/j.ejca.2006.05.002. Epub 2006 Jun 5.
7
Emergency department management of chemotherapy related febrile neutropenia: An opportunity to improve care.急诊科对化疗相关性发热性中性粒细胞减少症的管理：改善护理的机会。
Am J Emerg Med. 2021 Dec;50:5-9. doi: 10.1016/j.ajem.2021.07.008. Epub 2021 Jul 9.
8
Febrile neutropenia in hematologic malignancies.血液恶性肿瘤患者的中性粒细胞减少伴发热。
Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. doi: 10.1007/s11899-013-0171-4.
9
Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.治疗前炎症可预测小细胞肺癌一线化疗后发热性中性粒细胞减少和无进展生存期缩短。
Oncol Res Treat. 2018;41(9):506-512. doi: 10.1159/000488688. Epub 2018 Aug 8.
10
Usefulness of complete blood count parameters to predict poor outcomes in cancer patients with febrile neutropenia presenting to the emergency department.全血细胞计数参数在预测因发热性中性粒细胞减少症而就诊于急诊科的癌症患者不良结局中的作用。
Ann Med. 2022 Dec;54(1):599-609. doi: 10.1080/07853890.2022.2031271.
引用本文的文献
1
Bacterial agents and antibiotic resistance in febrile neutropaenia in Africa: A systematic review and meta-analysis.非洲发热性中性粒细胞减少症中的细菌病原体与抗生素耐药性：一项系统评价与荟萃分析。
Afr J Lab Med. 2025 Aug 26;14(1):2816. doi: 10.4102/ajlm.v14i1.2816. eCollection 2025.
2
Do We Need Meropenem Treatment Beyond 7 Days in Febrile Neutropenic Patients: A Cost-Effectiveness Analysis.发热性中性粒细胞减少症患者美罗培南治疗超过7天是否必要：一项成本效益分析
Antibiotics (Basel). 2025 Jun 27;14(7):653. doi: 10.3390/antibiotics14070653.
3
Prescription patterns of supportive care medications among children receiving chemotherapy treatments at a major referral hospital in Tanzania: where are we in managing chemotherapy-induced toxicities?坦桑尼亚一家主要转诊医院接受化疗的儿童使用支持性护理药物的处方模式：我们在管理化疗引起的毒性方面处于什么水平？
Front Oncol. 2025 Feb 25;15:1444565. doi: 10.3389/fonc.2025.1444565. eCollection 2025.
4
Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia.发热性中性粒细胞减少症患者适当降阶梯使用美罗培南可改善临床结局。
J Glob Infect Dis. 2024 Dec 21;16(4):145-151. doi: 10.4103/jgid.jgid_192_23. eCollection 2024 Oct-Dec.
5
Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study.评估阿替利珠单抗对日本接受化疗的非小细胞肺癌患者发热性中性粒细胞减少症发生情况的影响：一项真实世界的上市后数据库研究。
Int J Clin Oncol. 2025 Feb;30(2):298-308. doi: 10.1007/s10147-024-02669-y. Epub 2024 Dec 16.
6
Comparison of Wireless Continuous Axillary and Core Temperature Measurement after Major Surgery.手术后无线连续腋窝和核心温度测量的比较。
Sensors (Basel). 2024 Jul 10;24(14):4469. doi: 10.3390/s24144469.
7
Severe febrile neutropenia and pancytopenia in a patient with advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab: a case report.一例接受阿替利珠单抗和贝伐单抗治疗的晚期肝细胞癌患者出现严重发热性中性粒细胞减少和全血细胞减少：病例报告
J Gastrointest Oncol. 2024 Jun 30;15(3):1324-1330. doi: 10.21037/jgo-24-290. Epub 2024 Jun 19.
8
Gut diversity and the resistome as biomarkers of febrile neutropenia outcome in paediatric oncology patients undergoing hematopoietic stem cell transplantation.肠道菌群多样性和耐药组作为儿童血液肿瘤患者造血干细胞移植后发热性中性粒细胞减少症结局的生物标志物。
Sci Rep. 2024 Mar 6;14(1):5504. doi: 10.1038/s41598-024-56242-8.
9
Comparison of global decolonization efficacy with mupirocin nasal drop and chlorhexidine mouthwash in acute leukemia patients: randomized clinical trial.比较莫匹罗星鼻滴和洗必泰漱口液在急性白血病患者中全身去定植效果的随机临床试验。
Support Care Cancer. 2023 Dec 19;32(1):42. doi: 10.1007/s00520-023-08232-1.
10
Pre-Chemotherapy Dental Screening: Is There Additional Diagnostic Value for a Panoramic Radiograph?化疗前口腔筛查：全景X线片是否具有额外的诊断价值？
Dent J (Basel). 2023 May 4;11(5):122. doi: 10.3390/dj11050122.
本文引用的文献
1
Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department.应用MASCC和CISNE风险分层评分识别急诊科低风险发热性中性粒细胞减少患者。
Ann Emerg Med. 2017 Jun;69(6):755-764. doi: 10.1016/j.annemergmed.2016.11.007. Epub 2016 Dec 29.
2
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.发热性中性粒细胞减少症的管理：ESMO临床实践指南
Ann Oncol. 2016 Sep;27(suppl 5):v111-v118. doi: 10.1093/annonc/mdw325.
3
Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study.疑似稳定发热性中性粒细胞减少症患者严重并发症的预测：来自 FINITE 研究前瞻性队列患者的临床稳定发热性中性粒细胞减少症指数的验证。
J Clin Oncol. 2015 Feb 10;33(5):465-71. doi: 10.1200/JCO.2014.57.2347. Epub 2015 Jan 5.
4
Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.转移性实体瘤患者化疗所致发热性中性粒细胞减少的风险和后果。
J Oncol Pract. 2015 Jan;11(1):47-54. doi: 10.1200/JOP.2014.001492. Epub 2014 Dec 9.
5
Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis.癌症中性粒细胞减少症患者的黏膜屏障损伤、发热和感染：引入发热性黏膜炎范例。
Br J Haematol. 2014 Nov;167(4):441-52. doi: 10.1111/bjh.13113. Epub 2014 Sep 6.
6
Management of febrile neutropenia in the era of bacterial resistance.细菌耐药时代的发热性中性粒细胞减少症管理
Ther Adv Infect Dis. 2013 Feb;1(1):37-43. doi: 10.1177/2049936113475610.
7
Distinct inflammatory mediator patterns characterize infectious and sterile systemic inflammation in febrile neutropenic hematology patients.发热性中性粒细胞减少症血液病患者的感染性和无菌性全身炎症具有不同的炎症介质特征。
PLoS One. 2014 Mar 18;9(3):e92319. doi: 10.1371/journal.pone.0092319. eCollection 2014.
8
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.住院和门诊环境中化疗引起的发热性中性粒细胞减少症的发病率、治疗及后果。
J Oncol Pharm Pract. 2014 Jun;20(3):190-8. doi: 10.1177/1078155213492450. Epub 2013 Jul 2.
9
Colony-stimulating factors for febrile neutropenia during cancer therapy.癌症治疗期间发热性中性粒细胞减少症的集落刺激因子。
N Engl J Med. 2013 Mar 21;368(12):1131-9. doi: 10.1056/NEJMct1210890.
10
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.多国癌症支持治疗协会（MASCC）风险指数评分：用于识别低危发热性中性粒细胞减少症癌症患者的 10 年应用。
Support Care Cancer. 2013 May;21(5):1487-95. doi: 10.1007/s00520-013-1758-y. Epub 2013 Feb 27.
Zotero 插件